https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-805
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-8052017-01-01 00:00:002019-02-15 08:36:11Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-07 / JCI Insight 2016 Jul;1(10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-07 / JCI Insight 2016 Jul;1(10)2016-07-07 00:00:002019-02-15 08:36:05PD-1 blockade enhances the vaccination-induced immune response in glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-21 / Immunity 2016 06;44(6):1255-69
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-21 / Immunity 2016 06;44(6):1255-692016-06-21 00:00:002019-02-15 08:35:58Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-452016-06-01 00:00:002016-06-01 00:00:00Emerging immunotherapies for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-01-06 / Viruses 2016 Jan;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-01-06 / Viruses 2016 Jan;8(1)2016-01-06 00:00:002019-02-15 08:36:16Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-09-01 / Cancer Biol Med 2015 Sep;12(3):201-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-09-01 / Cancer Biol Med 2015 Sep;12(3):201-82015-09-01 00:00:002019-02-15 08:35:54Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-02 / Front Immunol 2015;6:271
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-02 / Front Immunol 2015;6:2712015-06-02 00:00:002015-06-02 00:00:00Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-01 / Cancer Res. 2015 Jun;75(11):2139-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-01 / Cancer Res. 2015 Jun;75(11):2139-452015-06-01 00:00:002019-02-15 08:35:57Classifying Cancers Based on T-cell Infiltration and PD-L1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-09 / Cell 2015 Apr;161(2):205-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-09 / Cell 2015 Apr;161(2):205-142015-04-09 00:00:002019-02-15 08:35:55Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / Lancet Oncol. 2014 Jun;15(7):e257-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / Lancet Oncol. 2014 Jun;15(7):e257-672014-06-01 00:00:002019-02-15 08:35:59Clinical use of dendritic cells for cancer therapy
